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Abstract
Background: Oxaliplatin chemotherapy induced neuropathy is a dose related cumulative toxicity that manifests as
tingling, numbness, and chronic pain, compromising the quality of life and leading to discontinued chemotherapy.
Patients report marked hypersensitivity to cold stimuli at early stages of treatment, when sensory testing reveals
cold and heat hyperalgesia. This study examined the morphological and functional effects of oxaliplatin treatment
in cultured adult rat DRG neurons.
Results: 48 hour exposure to oxaliplatin resulted in dose related reduction in neurite length, density, and number
of neurons compared to vehicle treated controls, using Gap43 immunostaining. Neurons treated acutely with 20
μg/ml oxaliplatin showed significantly higher signal intensity for cyclic AMP immunofluorescence (160.5 ± 13 a.u.,
n = 3, P < 0.05), compared to controls (120.3 ± 4 a.u.). Calcium imaging showed significantly enhanced capsaicin
(TRPV1 agonist), responses after acute 20 μg/ml oxaliplatin treatment where the second of paired capsaicin
responses increased from 80.7 ± 0.6% without oxaliplatin, to 171.26 ± 29% with oxaliplatin, (n = 6 paired t test,
P < 0.05); this was reduced to 81.42 ± 8.1% (P < 0.05), by pretretreatment with the cannabinoid CB2 receptor
agonist GW 833972. Chronic oxaliplatin treatment also resulted in dose related increases in capsaicin responses.
Similarly, second responses to icilin (TRPA1/TRPM8 agonist), were enhanced after acute (143.85 ± 7%, P = 0.004,
unpaired t test, n = 3), and chronic (119.7 ± 11.8%, P < 0.05, n = 3) oxaliplatin treatment, compared to control
(85.3 ± 1.7%). Responses to the selective TRPM8 agonist WS-12 were not affected.
Conclusions: Oxaliplatin treatment induces TRP sensitization mediated by increased intracellular cAMP, which may
cause neuronal damage. These effects may be mitigated by co-treatment with adenylyl cyclase inhibitors, like CB2
agonists, to alleviate the neurotoxic effects of oxaliplatin.
Background
Though advances in cancer detection and therapy have
significantly advanced life expectancy in cancer patients,
quality of life may be severely compromised due to the
development of painful neuropathy [1-4]. Chemotherapy-
induced peripheral neuropathy is a common, rapidly
induced effect observed soon after administration of anti-
cancer agents [5-7] resulting in numbness, tingling and
pain distributed in a distal stocking-and-glove pattern
[8,9]. Oxaliplatin is a highly active antineoplastic agent,
licensed for treating colorectal cancer, that contains a pla-
tinum complex with a 1,2-diaminocyclohexane (DACH)
carrier ligand designed to overcome resistance to other
antineoplastic agents [10]. The volume of distribution of
platinum is high, due to the lipophilicity of oxaliplatin
metabolites, which bind irreversibly to proteins, DNA and
other cellular molecules. The terminal half-life of oxalipla-
tin is long, and neurotoxicity is very common in patients
treated with this drug, with 68% experiencing some degree
of toxicity. The dose-limiting toxicity is exacerbated
by exposure to cold [11-14] at doses of or greater than
135 mg/m2, with early development of allodynia and
hypersensitivity to heat and cold stimuli [15].
Animal models have reproduced some of the effects of
the development of neuropathy after treatment with
chemotherapeutic agents, but the mechanism remains
unclear. Various treatments have been suggested to pro-
vide symptomatic relief for chemotherapy induced neu-
rotoxicity [16,17] but with limited or no efficacy.
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Since thermal hypersensitivity is a significant early con-
sequence of oxaliplatin treatment, we investigated the
involvement of the ion channels expressed by nociceptors
involved in thermosensation. These plasma membrane
bound ion channels belong to the transient receptor
potential (TRP), superfamily of receptors [18]. TRPV1
(vanilloid subtype 1), is activated by noxious heat (>43°C)
[19] capsaicin, low pH, the inflammatory mediators ara-
chidonic acid [20] and bradykinin [21] leading to the per-
ception of pain, and thermal hypersensitivity [22]. The
sensitivity and expression of TRPV1 is modulated by the
neurotrophins nerve growth factor (NGF) [23-25] and
glial cell-line derived neurotrophic factor (GDNF) in
rodents [26] and humans [27]. The levels of NGF, GDNF
and its receptor ret are increased in injured human per-
ipheral nerves and ganglia [28,29] and in tissues with
chronic inflammation [30-32]. TRPV1 expression is upre-
gulated in conditions of chronic pain [33-35] for which it
is an important target. As oxaliplatin treated individuals
report hypersensitivity to cold stimuli during or soon
after infusion, we examined the functional effects of
acute oxaliplatin treatment on TRPM8 and TRPA1, two
ion channels involved in cool and noxious cold percep-
tion respectively. TRPA1 is activated by temperatures
less than 17°C, the chemicals mustard oil and cinnamal-
dehyde (CA), and the cooling agents icilin and menthol;
it is expressed in nociceptors, and involved in pain per-
ception although there is inconsistent evidence for its
role in cold detection [36-42]. TRPA1 is colocalized with
30% - 50% TRPV1 expressing neurons in rodent [43] and
human DRG, where the expression of both channels is
increased after injury [44]. Like TRPV1, the responses of
TRPA1 to CA demonstrate tachyphylaxis, and are
enhanced in the presence of NGF, GDNF (also upregu-
lated in conditions of chronic pain), and NT3 [44].
TRPM8 (subtype melastatin 8), is expressed in a distinct
subset of nociceptors, and activated by cool temperature
(<25°C), menthol, icilin [45,46], and the carboxyamide
derivative WS-12 [47]. Here, we describe the morpholo-
gical and functional effects of oxaliplatin treatment in
cultured adult rat DRG neurons.
Results
The cultured neurons had extended neurites by 24
hours after plating, when the oxaliplatin was added, and
the morphological effects of oxaliplatin treatment were
apparent with phase-contrast microscopy 24 hours later.
Measurements taken 48 hours post oxaliplatin treatment
showed reduced neurite length, density and number of
surviving neurons, effects that were more pronounced
with the higher doses of 20 μg/ml and 50 μg/ml than
with the lower dose of 5 μg/ml oxaliplatin (Figure 1).
These effects were confirmed by Gap43 immunostaining
which showed that oxaliplatin-treated neurons had
thinner, shorter, vesiculated neurites, which appeared to
be disintegrated, leaving a faintly positive halo of neurite
fragments around the cell bodies (Figure 2). Gap43
immunostaining appeared patchy and less intense in
oxaliplatin-treated neurons compared with control neu-
rons, and was strongest at the cell body and diminished
Figure 1 Phase contrast photomicrographs of cultured adult
rat DRG neurons. A. without oxaliplatin; B. after 48 hour treatment
with 5 μg/ml oxaliplatin, C. 20 μg/ml oxaliplatin and D. 50 μg/ml
oxaliplatin, showing a dose-related loss of neurite integrity, loss of
cell bodies, and accumulation of cell debris. Bar = 50 μm.
Figure 2 Gap 43 immunostaining in adult rat DRG neurons
in vitro. A. without oxaliplatin treatment, DRG neurons are densely
distributed and the cell bodies and neurites are intensely positive
for Gap43 immunostaining (green), with long, robust and profusely
branched neurites. B. Neurons treated with 5 μg/ml oxaliplatin have
shorter, less dense neurites (double arrowheads), and reduced
intensity of Gap43 immunostaining (double arrowheads). C. after 20
μg/ml and D. 50 μg/ml oxaliplatin treatment, there is a dose related
loss of neurites (double arrowheads), cell bodies (single arrowheads)
and loss of Gap43 immunostaining. Bar = 30 μm.
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in the neurites (Figure 2). The maximum average neur-
ite length in control neurons was 525.3 ± 29.1 μm
(mean ± s.e.m., average of 3 experiments, total 39 neu-
rons). After 48 hours incubation with 5 μg/ml oxalipla-
tin, the maximum neurite length was significantly
reduced to 351.6 ± 23.7 μm (P < 0.05, total 27 neurons),
300.6 ± 23 μm after 20 μg/ml oxaliplatin (P < 0.01, total
20 neurons), and 130.3 ± 67.6 μm after 50 μg/ml oxali-
platin (P < 0.01, total 10 neurons) (Figure 3A). Data are
derived from n = 3 culture preparations for each con-
centration, in each experiment. The number of Gap43-
positive neurons was reduced with increasing oxaliplatin
concentration, as was the proportion of neurite-bearing
neurons (averages from more than 150 neurons for each
concentration, n = 3) (Figure 3B). The number of neu-
rons surviving after oxaliplatin treatment was reduced to
29.6 ± 6.4% (total 460 neurons, P = 0.0008), with 5 μg/
ml oxaliplatin, 41.7 ± 11% (total 658 neurons, P = 0.01),
with 20 μg/ml oxaliplatin, and 28 ± 2.3% (total 435 neu-
rons, P = 0.0002), with 50 μg/ml oxaliplatin, expressed
as a percentage ± s.e.m. of vehicle treated neurons (total
1543 neurons) (Figure 3C). cAMP levels in oxaliplatin
treated neurons were observed to be significantly higher
(160.5 ± 13 a.u., n = 3, 93 neurons P < 0.05), than the
vehicle treated neurons (120.3 ± 4 a.u., P < 0.05, n = 3,
50 neurons) and higher than positive controls treated
with 500 μg/ml 8-bromo-cAMP (140.45 ± 10, n = 3,
102 neurons) (Figure 4A and 4B).
Capsaicin responses
Functional studies using calcium imaging showed that
vehicle treated neurons produced a smaller second
response to capsaicin (80.7 ± 0.6%, n = 4, 13 neurons,
Figures 5B and 6A), compared with the first response
(100 ± 0.034%), due to desensitization. Neurons that had
been acutely treated with 20 μg/ml oxaliplatin for 10
minutes after the first capsaicin stimulus, showed a
Figure 3 Morphological effects of oxaliplatin treated neurons.
A. Dose-related decrease in maximum neurite length in oxaliplatin
treated adult rat DRG neurons in vitro; 33% reduction after 5 μg/ml
oxaliplatin, 42.7% reduction after 20 μg/ml, and 75% reduction after
50 μg/ml oxaliplatin treatment. B. Decrease in the percentage of
Gap43 positive neurons bearing neurites (solid bars) and increased
proportion of neurons without neurites (clear bars) after treatment
with increasing oxaliplatin concentration. C. The number of neurons
surviving after 48 hours oxaliplatin treatment, expressed as a
percentage of vehicle treated neurons was significantly reduced
after treatment with 5, 20 and 50 μg/ml oxaliplatin.
Figure 4 Increased cAMP signal intensity in oxaliplatin treated
neurons. A. Immunofluorescence images of cAMP positive adult rat
DRG neurons acutely treated with 8-bromo-cAMP (positive control),
or oxaliplatin for 15 minutes, compared to vehicle treated neurons.
Bar = 50 μm. B. Fluorescence signal intensity for cAMP
immunostaining (arbitrary units), was increased in oxaliplatin treated
adult rat DRG neurons compared to positive controls, and
significantly higher than vehicle treated neurons.
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significantly enhanced second response to capsaicin
(paired t test, P < 0.05, 171.26 ± 29.6%, n = 6, 16 neu-
rons, Figure 5D and 6A), compared to the first response
and also when compared with the second response to
capsaicin without oxaliplatin (n = 4, 13 neurons, unpaired
t Test, P < 0.05). (Figure 5C). Further, some neurons that
had not responded to the first response, showed a
response to the second capsaicin stimulus after the addi-
tion of oxaliplatin (traces 2,3 and 4 in Figure 5D). Prein-
cubation with the CB2 agonist GW833972 eliminated the
enhancement seen with oxaliplatin, reducing the second
response to 81.42 ± 8.1% of the first response (P < 0.05 n
= 3, 12 neurons) (Figure 6A). Neurons treated with 5, 20
or 50 μg/ml oxaliplatin for 48 hours (n = 3), were stimu-
lated with a single application of 200 nM capsaicin, and
compared with responses in vehicle treated neurons (n =
5, 27 neurons, Figure 6B). There was a dose-related
enhancement of responses, which was significantly
greater in neurons treated with 20 (P = 0.003, 22 neu-
rons), and 50 (P = 0.002, 27 neurons) μg/ml oxaliplatin,
but not with 5 μg/ml oxaliplatin (n.s. P = 0.1, 22
neurons).
Icilin responses
In vehicle treated neurons not treated with oxaliplatin,
the second response to 1 μM icilin was reduced com-
pared with the first response (85.3 ± 1.7%, n = 3, 8 neu-
rons, Figure 6C), while 5-10 minute treatment with 20
μg/ml oxaliplatin enhanced the second response com-
pared with the first response (143.85 ± 7%, P = 0.004,
unpaired t test, n = 3, 11 neurons, Figure 6C). Similarly,
chronic treatment (24 hours) with 20 μg/ml oxaliplatin
also resulted in significantly enhanced second responses
to 1 μM icilin compared to those without oxaliplatin
(119.71 ± 11.8%, P < 0.05, n = 3, 11 neurons). Sensitiza-
tion of icilin responses were unaffected by pretreatment
with 5 μM CB2 agonist GW 833972 (not shown).
WS-12 responses
Responses to the second of a pair of 20 μM WS-12 sti-
muli, were reduced in vehicle treated neurons compared
with the first response (83.39 ± 16.1%, n = 5, 21 neu-
rons, Figure 6D). In the presence of oxaliplatin, there
was no change in the average magnitude of the second
response (84.6 ± 16.4%, n = 7, 24 neurons), although
some neurons responded to the second stimulus but not
the first. Spontaneous activity was observed in some
neurons after the addition of oxaliplatin. Application of
oxaliplatin or vehicle did not activate calcium influx in
the neurons, at the concentrations used.
Discussion
Morphological effects of oxaliplatin treatment
This study was aimed at understanding the cellular and
molecular mechanisms involved in oxaliplatin-induced
neuropathy, and showed that adult rat DRG neurons
treated with oxaliplatin in vitro, undergo dose-depen-
dent loss of neurite length, density, Gap43 expression,
and neuronal number (Figures 1, 2, 3). In addition to
these morphological changes, increased cAMP levels in
oxaliplatin-treated neurons (Figure 4) correlated with
functional effects of TRPV1 and TRPA1 sensitization,
not observed for TRPM8, after acute and chronic treat-
ment with oxaliplatin (Figure 6). The doses used in our
study (5, 20, 50 μg/ml i.e. 12, 48 and 120 μM respec-
tively) were higher than another study (1-10 μg/ml)
investigating the effects of oxaliplatin in embryonic
(E15) rat DRG [48], but with similar outcomes for neu-
ronal survival and inhibition of neurite outgrowth.
Other studies have utilised higher oxaliplatin concentra-
tions of 250 μM on rat DRG neurons [49], and 100 and
500 μM on rat sciatic nerve [50]. Thus, while oxaliplatin
targets rapidly dividing tumour cells by the formation of
DNA adducts, post mitotic neurons are also affected,
possibly by disruption of the synthesis of cytoskeletal
elements essential for axon transport of ion channels
and other membrane proteins, which are actively
Figure 5 Sensitization of capsaicin responses by acute
oxaliplatin treatment: A. Representative trace showing baseline
340/380 intracellular ratio in a DRG neuron and its increase in
response to addition of 200 nM capsaicin (arrow) to test for
capsaicin sensitivity. B. Following washout of medium, a second
stimulus of 1 μM capsaicin (arrow) after 30 minutes gave a smaller
second response compared with the first response (in A), due to
desensitization. C. Same as in Figure 5A, showing traces 1,2,3,4 from
4 individual neurons, where trace 1 shows increased 340/380 ratio
in response to added 200 nM capsaicin (arrow), but not traces 2,3
or 4. D. Incubation with 20 μg/ml oxaliplatin for 10 minutes after
the first stimulus and washout significantly enhanced the response
to 1 μM capsaicin (arrow, trace 1) and evoked responses in
previously unresponsive neurons (traces 2 and 4).
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recycled from the terminals. Evidence for this may be
derived from the diminished Gap43 immunostaining fol-
lowing oxaliplatin treatment. Gap43 is a cytoskeletal,
growth associated protein expressed in developing and
regenerating DRG neurons [51]; it is rapidly transported
to the nerve terminals after synthesis, and is essential
for the maintenance of neurites [52]. Oxaliplatin thus
appears to have similar morphological effects to cispla-
tin, taxol and paclitaxel [53-55]. The dose dependent
reduction of neurite length indicates damage that could
result in disruption of nerve terminals and signal trans-
duction components, and provide a basis for the stock-
ing and glove distribution of sensory abnormalities
experienced by chemotherapy recipients. Damaged
Figure 6 Sensitization of capsaicin responses after acute (A) and chronic (B) oxaliplatin treatment; Sensitization of responses to icilin
(C), but not WS12 (D), after oxaliplatin treatment. A. Graph showing the average magnitude of desensitization (2nd bar) normalised to the
first response (1st bar) in vehicle treated neurons. Acute oxaliplatin treatment resulted in significantly enhanced second responses (3rd bar),
compared to the first capsaicin response, that was reversed by preincubation with 5 μM CB2 agonist GW833972 (4th bar). B. Chronic treatment
with oxaliplatin for 48 hours also enhanced responses to 200 nM capsaicin (n.s. at 5 μg/ml oxaliplatin, but highly significant at 20 and 50 μg/ml
oxaliplatin). C. Vehicle treated neurons responded to 1 μM icilin with calcium influx (1st bar), and a smaller second response following washout
(2nd bar). Pretreatment with 20 μg/ml oxaliplatin before the second icilin stimulus significantly enhanced responses to 1 μM icilin (3rd bar), and
significantly higher than the second icilin response without oxaliplatin (P = 0.005). Similarly, chronic oxaliplatin treatment (20 μg/ml for 24 hours),
also resulted in significantly enhanced second responses to 1 μM icilin compared to those without oxaliplatin (P < 0.05). D. Vehicle treated
neurons responded to the TRPM8 specific ligand WS-12 (20 μM stimulus), with calcium influx (1st bar). Following washout, a second 20 μM WS-
12 stimulus resulted in a reduced response (2nd bar), that was unaffected by the presence of oxaliplatin.
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afferent neurites are capable of sprouting from their per-
ipheral terminals and reconnecting with their peripheral
target tissue, so that resolution of dysaesthesia and para-
esthesia would be expected to occur with time after dis-
continuation of chemotherapy. However loss of sensory
neurons due to cell death is likely to produce permanent
sensory deficits due to the inability of sensory neurons
to be replaced, thus creating an imbalance between the
surviving fibre types with respect to modality. Further,
as injured afferent fibres are capable of generating ecto-
pic signals from their damaged terminals and cell bodies
within the DRG [56] chemotherapy induced neuronal
damage may lead to chronic pain.
Oxaliplatin pharmacokinetics
Studies in patients have indicated that oxaliplatin binds
irreversibly to plasma proteins and has a long half life
which could lead to the cumulative dose related toxicity.
Thus while the doses used in our study were higher
than the maximum concentration levels (4.81 ± 1.83 μg/
ml), which is closest to our lowest dose of 5 μg/ml)
observed in plasma ultrafiltrate of patients treated with
a single oxaliplatin infusion [57], they may represent the
levels present in tissues including peripheral nerves,
accumulated during the course of treatment. AUC0-inf
(area under the curve) values of 278 ± 81 μg/ml*h fol-
lowing a single 4 hour infusion at 130 mg/m2 (cycle 1)
have been reported for plasma platinum [57].
Animal models of chemotherapy mediated neuropathy
Rodents treated with paclitaxel and vincristine devel-
oped a partial degeneration of terminal arbours in the
epidermis, increased spontaneous discharge of periph-
eral nerve fibres [58], reduced nerve conduction velocity
after cisplatin and paclitaxel administration [59], and
thermal hyperalgesia, with upregulation of TRPV1,
TRPM8 and TRPA1 mRNA several hours after cisplatin
and oxaliplatin treatment [60].
Functional effects of oxaliplatin treatment on TRPV1,
TRPA1/M8
We have studied the functional effects of oxaliplatin on
the neuronal characteristic of desensitization (tachyphy-
laxis) due to repeat stimulation [61-63]. The desensitiza-
tion observed in our experiments was between the first
capsaicin stimulus of 200 nM and the second stimulus of
1 μM, 30 minutes after washout of medium; this protocol
has been previously described [64] and the modest desen-
sitization is attributed to the combination of growth fac-
tors used for culturing the neurons, and the long gap
between the first and second stimuli. However, we
observed acute sensitization of TRPV1 within 10 minutes
of applying 20 μg/ml oxaliplatin, seen as significantly
enhanced capsaicin responses with calcium imaging,
compared to the desensitization observed in vehicle trea-
ted neurons (Figures 5 and 6A) indicating a modulatory
effect of oxaliplatin on the sensitivity of TRPV1. Chronic
oxaliplatin treatment (48 hours) also resulted in signifi-
cantly enhanced dose related responses to 200 nM cap-
saicin, in contrast to vehicle treated neurons (Figure 6C).
Some neurons developed spontaneous activity after oxali-
platin application, or showed a response to the second
capsaicin stimulus following oxaliplation addition, but
not the first capsaicin stimulus (traces 2, 4, in Figure 5D).
Thus oxaliplatin differs from Ara C (cytosine arabinoside
- used for treating leukemia), which had the effect of
abolishing capsaicin responses by blocking the insertion
of TRPV1 ion channels in the cell membrane of human
DRG neurons, but causing hypersensitivity when Ara C
treatment was stopped, due to the reappearance of
TRPV1 in the cell membrane [65]. As oxaliplatin applica-
tion itself did not result in calcium influx, it appears not
to directly activate the TRPV1 receptor, but may bring
about the observed effects via a second messenger, such
as cAMP, which we found was significantly increased in
oxaliplatin treated neurons compared to controls (Figure
4). The rapid sensitization of TRPV1, within minutes of
applying oxaliplatin as observed in this study, probably
occurs via post translational modification, in a manner
similar to that observed in the rapid membrane insertion
of TRPV1 ion channels following activation of protein
kinase A and phosphorylation of TRPV1 [25,66,67].
Mechanism of TRPV1 sensitization and effect
of CB2 agonist
Since adenylyl cyclase activation is involved in TRPV1
sensitization via cAMP [68] by phosphorylation of
TRPV1 [69], we compared cAMP expression in vehicle
treated neurons, positive controls i.e. neurons treated
with membrane permeant 8-bromo-cAMP, and in neu-
rons acutely treated with oxaliplatin, using immunofluor-
escence. The significant increase in cAMP observed in
oxaliplatin treated neurons, correlated well with the func-
tional data, which showed acute sensitization following
oxaliplatin treatment. This observation is strengthened
by the abolition of oxaliplatin mediated sensitization of
capsaicin responses by preincubation with the CB2 (can-
nabinoid receptor subtype 2) agonist GW833972 (Figure
6A). CB2 mediated inhibition of capsaicin responses has
been shown in rats [70], and guinea pigs [71,72],
mediated by TRPV1 dephosphorylation [73]. CB2 recep-
tors are G protein coupled receptors expressed by DRG
neurons, and CB2 agonists have been shown to inhibit
adenylyl cyclase, and reduce cAMP, to inhibit TRPV1
sensitization in human sensory neurons in vitro [64]. On
the basis of these results, it can be hypothesized that inhi-
bitors of adenylyl cyclase may be expected to ameliorate
TRPV1 mediated hypersensitivity following oxaliplatin
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chemotherapy. The acute effects of oxaliplatin observed
in this study may have been brought about by activation
of adenylyl cyclase and a consequent increase in cAMP
leading to TRPV1 phosphorylation and sensitization.
This is likely to cause further excitotoxicity by increased
calcium influx and may be responsible for structural
damage such as neurite loss, which could potentially lead
to neuropathic pain.
Effect of oxaliplatin on TRPA1/M8 function
As the infusion of oxaliplatin is accompanied by the
symptom of hypersensitivity to cold stimuli in patients,
we examined the involvement of the cool receptor
TRPM8, and the noxious cold receptor TRPA1, which
are activated by the chemicals menthol and icilin
[74,75]. Identification of icilin sensitive neurones and
examination of their subsequent responses in the pre-
sence of oxaliplatin required repeated stimulation with
icilin, which resulted in 14.7% reduction of the second
response. TRPM8 is subject to desensitization on repeat
stimulation [40,76], as is TRPA1. Acute and chronic
oxaliplatin treatment resulted in sensitization of icilin
responses indicating that either one or both channels
could be affected (Figure 6C). In order to identify which
of these channels was involved, we used the TRPM8
specific carboxyamide derivative WS-12 [40], but no
consistent sensitization of WS-12 responses was
observed after oxaliplatin treatment (Figure 6D), indicat-
ing that TRPM8 may not be involved in oxaliplatin
mediated effects. Our conclusion that oxaliplatin affects
TRPA1 rather than TRPM8, is based on the sensitiza-
tion of icilin responses observed after oxaliplatin treat-
ment but not of the responses using the TRPM8
specific ligand WS12; this is an indirect approach to dis-
tinguish between the two ion channels, and may repre-
sent a limitation of this study. As the low dose used
(1 μM) is closer to the EC50 for TRPM8 [40], than for
TRPA1, it is possible that TRPM8 rather than TRPA1 is
involved in oxaliplatin mediated cold hypersensitivity;
this would have to be confirmed by future studies using
thermal stimuli.
A clinical effect on nerve fibres expressing TRPA1
could account for early symptomatic cold hypersensitiv-
ity, while the cold and heat hyperalgesia on sensory test-
ing may result from sensitization of TRPA1 and TRPV1
ion channels respectively. As the clinical symptoms can
be acute, a postranslational mechanism of activation is
more likely than changes in gene expression, in the
immediate phase.
Conclusions
This is the first study to describe sensitization of TRPV1
and TRPA1 and/or TRPM8 in a model of oxaliplatin
induced neuropathy, the role of cAMP in mediating the
sensitization, and the effectiveness of a CB2 agonist in
mitigating it.
Methods
Bilateral DRG from all spinal levels were aseptically har-
vested from 19 freshly sacrificed adult female Wistar
rats (250 grams), in Ham’s F12 medium, enzyme
digested in 0.2% collagenase (Worthington type IV)/
0.5% dispase for 3 hours at 37°C, and dissociated in
modified BSF2 medium [77], containing 2% fetal calf
serum and soy-bean trypsin inhibitor (1 mg/ml), to
obtain a single cell suspension. 100 μl neuronal suspen-
sion was plated on collagen (type I, 50 μg/ml), and lami-
nin (20 μg/ml), coated MatTek dishes (glass bottomed
plastic petri dishes), in BSF2 medium and incubated at
37°C in a humid environment, for 30 minutes before
adding 2 mls BSF2 containing 50 ng/ml each NT3 and
GDNF, 100 ng/ml NGF, to each dish. 24 hours later,
oxaliplatin, was added to some of the cultures at 5 μg/
ml (12 μM), 20 μg/ml (48 μM), 50 μg/ml (120 μM), or
vehicle (0.4% distilled water).
Immunostaining
Cultures were fixed 48 hours after oxaliplatin treatment,
with 4% paraformaldehyde (PFA), for 15 minutes,
washed in PBS, permeabilised with methanol (-20°C,
3 minutes), washed in PBS and incubated with primary
antibody, mouse monoclonal anti Gap43 (1: 200). This
was followed by 3 PBS washes and secondary antibody
Alexa Fluor 488 (Molecular probes, 1: 200), for 45 min-
utes at room temperature, washed with PBS, and
mounted in Citifluor containing Dabco (antifade agent).
Cyclic AMP (cAMP) immuostaining was performed in
vehicle treated neurones, and neurons treated with 20
μg/ml oxaliplatin or 500 μM 8-bromo cAMP (Calbio-
chem, positive controls) for 15 minutes. Following PFA
fixation, immunostaining with primary rabbit polyclonal
antibody to cAMP (AB306, Millipore, USA, 1:1000), and
Alexa 546 secondary antibody, was performed as above.
Images were acquired with Smartcapture 3 (Digital
Scientific, Cambridge UK), connected to an upright
Olympus BX61 microscope, after confirming the
absence of immunostaining in negative controls where
the primary antibody had been omitted. Adobe Photo-
shop C53 software was used to measure the maximum
neurite lengths in Gap43 immunostained neurons, and
cells with and without neurites were counted in each
group (n = 3 for each group). Images of cAMP immu-
nostaining were captured using 0.2 seconds exposure
time, and fluorescence intensity was measured (arbitrary
units a.u.) with Metamorph software (Molecular
Devices), imported and analysed with Excel software.
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Calcium imaging - capsaicin responses
Neuronal cultures were loaded with the calcium indica-
tor dye Fura 2 AM, (Molecular Probes, 2 μM, 45 min-
utes at 37°C), in phenol-red free Hank’s balanced salt
solution (HBSS), containing 0.1% BSA, washed and
incubated in HBSS containing 0.5% BSA for 20 minutes,
and baseline changes in bound/unbound calcium ratio
(340/380 lem nm), in response to capsaicin stimulation
were monitored as previously described [63]. Acute
effects of oxaliplatin were determined in normal neu-
rons stimulated with a test dose of 200 nM capsaicin to
identify capsaicin sensitivity, followed by washout and a
second capsaicin stimulus of 1 μM after 30 minutes; this
was compared with the responses to 1 μM capsaicin in a
separate group of neurons, preincubated with 20 μg/ml
oxaliplatin, or the cannabinoid receptor subtype 2
(CB2), agonist GW 833972 and oxaliplatin, for 10 min-
utes following the 200 nM test dose of capsaicin and
washout. Chronic effects of oxaliplatin were determined
by measuring the first response to 200 nM capsaicin in
neurons pretreated with oxaliplatin for 24-48 hours and
compared with vehicle treated controls.
Icilin responses
Fura 2 loaded normal untreated neurons were stimulated
with a pair of stimuli of 1 μM icilin, separated by washout
of medium and a 10 minute rest period. The responses
were compared with those obtained after acute application
of 20 μg/ml oxaliplatin before the second icilin stimulus.
Chronic effects of oxaliplatin treatment were determined
in neurons treated with 20 μg/ml oxaliplatin for 24-48
hours, with repeat stimulation using 1 μM icilin.
WS-12 responses
The TRPM8 specific ligand WS-12 was used in an identi-
cal protocol as icilin, with paired stimuli of 20 μM, sepa-
rated by washout of medium and a 10 minute rest period
between the two stimuli. The responses were compared
with those from neurons acutely treated with 20 μg/ml
oxaliplatin before the second WS-12 stimulus. Students
t-test was used to compare groups and results are given as
Mean ± SEM, n = number of culture preparations and n.s.
indicates ‘not significant’. P < 0.05 was set as the level for
statistical significance. Capsaicin was freshly prepared in
ethanol at 400× final concentration from 20 mM stock
solution (in DMSO aliquoted and stored at -20°C). Oxali-
platin was dissolved in sterile distilled water at 5 mg/ml
concentration, and stored as aliquots at -20°C, which were
freshly thawed prior to use. Icilin and WS-12 stocks were
prepared at 400× final concentration in ethanol; all chemi-
cals were purchased from Sigma, U.K. unless stated
otherwise. GW833972 is 2-[(2,4-dichlorophenyl)amino]-
N-(4- pyridinylmethyl)-4-(trifluoromethyl)-5 pyrimidine
carboxamide, CB2 EC50 = 60 nM [kind gift of
GlaxoSmithKline, UK]. WS-12 is 2 S,5R-2-Isopropyl-N-(4-
methoxyphenyl)-5-methylcyclohexanecarboxyamide. Rats
were housed and tissues were harvested according to UK
Home Office guidelines.
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